Connect your AI

Arcus Biosciences RCUS AFS Securities

AFS Securities at other companies

Kymera TherapeuticsKYMR

$894.72M+186%

Arcutis Biotherapeutics, Inc.ARQT

$48.87M—

IncyteINCY

——

Summit TherapeuticsSMMT

——

ExelixisEXEL

——

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's AFS securities?: Arcus Biosciences (RCUS) reported AFS securities of $54M in Q1 2026.
How has Arcus Biosciences's AFS securities changed year-over-year?: Arcus Biosciences's AFS securities increased by 575.0% year-over-year, from $8M to $54M.
What is the long-term trend for Arcus Biosciences's AFS securities?: Over 5 years (2020 to 2025), Arcus Biosciences's AFS securities has grown at a 35.1% compound annual growth rate (CAGR), from $6.44M to $29M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.